EdgarLookup

Nutanix, Inc. — Financial Data

Annual figures from SEC EDGAR XBRL filings (10-K)

These figures are extracted directly from XBRL-tagged financial statements that Nutanix, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.

Overview All Filings Annual Quarterly Insiders
7.4%
Profit Margin
Net income ÷ revenue
5.7%
Return on Assets
Net income ÷ assets
-5.73x
Debt-to-Equity
Total liabilities ÷ equity
+18.1%
Revenue Growth
Year over year

Revenue

Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.

Fiscal Year Period End Value Filed
FY2025 Jul 31, 2025 $2.54B Sep 24, 2025
FY2025 Jul 31, 2024 $2.15B Sep 24, 2025
FY2025 Jul 31, 2023 $1.86B Sep 24, 2025
FY2024 Jul 31, 2022 $1.58B Sep 19, 2024
FY2023 Jul 31, 2021 $1.39B Sep 21, 2023
FY2020 Jul 31, 2020 $327.87M Sep 23, 2020
FY2020 Apr 30, 2020 $318.27M Sep 23, 2020
FY2020 Jan 31, 2020 $346.77M Sep 23, 2020
FY2020 Oct 31, 2019 $314.77M Sep 23, 2020
FY2020 Jul 31, 2019 $299.88M Sep 23, 2020

Revenue (Net Sales)

Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.

Fiscal Year Period End Value Filed
FY2017 Jul 31, 2017 $226.10M Sep 18, 2017
FY2017 Apr 30, 2017 $191.76M Sep 18, 2017
FY2017 Jan 31, 2017 $182.20M Sep 18, 2017
FY2017 Oct 31, 2016 $166.81M Sep 18, 2017
FY2017 Jul 31, 2016 $139.79M Sep 18, 2017
FY2017 Apr 30, 2016 $114.69M Sep 18, 2017
FY2017 Jan 31, 2016 $102.70M Sep 18, 2017
FY2017 Oct 31, 2015 $87.76M Sep 18, 2017
FY2017 Jul 31, 2015 $241.43M Sep 18, 2017

Gross Profit

Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.

Fiscal Year Period End Value Filed
FY2025 Jul 31, 2025 $2.20B Sep 24, 2025
FY2025 Jul 31, 2024 $1.82B Sep 24, 2025
FY2025 Jul 31, 2023 $1.53B Sep 24, 2025
FY2024 Jul 31, 2022 $1.26B Sep 19, 2024
FY2023 Jul 31, 2021 $1.10B Sep 21, 2023
FY2020 Jul 31, 2020 $260.90M Sep 23, 2020
FY2020 Apr 30, 2020 $245.98M Sep 23, 2020
FY2020 Jan 31, 2020 $271.54M Sep 23, 2020
FY2020 Oct 31, 2019 $242.57M Sep 23, 2020
FY2020 Jul 31, 2019 $230.91M Sep 23, 2020

Net Income

The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.

Fiscal Year Period End Value Filed
FY2025 Jul 31, 2025 $188.37M Sep 24, 2025
FY2025 Jul 31, 2024 ($124.78M) Sep 24, 2025
FY2025 Jul 31, 2023 ($254.56M) Sep 24, 2025
FY2024 Jul 31, 2022 ($798.95M) Sep 19, 2024
FY2023 Jul 31, 2021 ($1.04B) Sep 21, 2023
FY2020 Jul 31, 2020 ($185.35M) Sep 23, 2020
FY2020 Apr 30, 2020 ($240.67M) Sep 23, 2020
FY2020 Jan 31, 2020 ($217.56M) Sep 23, 2020
FY2020 Oct 31, 2019 ($229.30M) Sep 23, 2020
FY2020 Jul 31, 2019 ($194.34M) Sep 23, 2020

Operating Income

Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.

Fiscal Year Period End Value Filed
FY2025 Jul 31, 2025 $172.54M Sep 24, 2025
FY2025 Jul 31, 2024 $7.56M Sep 24, 2025
FY2025 Jul 31, 2023 ($207.15M) Sep 24, 2025
FY2024 Jul 31, 2022 ($458.85M) Sep 19, 2024
FY2023 Jul 31, 2021 ($662.11M) Sep 21, 2023
FY2020 Jul 31, 2020 ($171.35M) Sep 23, 2020
FY2020 Apr 30, 2020 ($230.17M) Sep 23, 2020
FY2020 Jan 31, 2020 ($207.06M) Sep 23, 2020
FY2020 Oct 31, 2019 ($220.34M) Sep 23, 2020
FY2020 Jul 31, 2019 ($182.52M) Sep 23, 2020

R&D Expense

Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.

Fiscal Year Period End Value Filed
FY2025 Jul 31, 2025 $736.82M Sep 24, 2025
FY2025 Jul 31, 2024 $638.99M Sep 24, 2025
FY2025 Jul 31, 2023 $580.96M Sep 24, 2025
FY2024 Jul 31, 2022 $573.00M Sep 19, 2024
FY2023 Jul 31, 2021 $558.01M Sep 21, 2023
FY2020 Jul 31, 2020 $135.34M Sep 23, 2020
FY2020 Apr 30, 2020 $141.35M Sep 23, 2020
FY2020 Jan 31, 2020 $139.09M Sep 23, 2020
FY2020 Oct 31, 2019 $138.21M Sep 23, 2020
FY2020 Jul 31, 2019 $129.17M Sep 23, 2020

Operating Cash Flow

Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.

Fiscal Year Period End Value Filed
FY2025 Jul 31, 2025 $821.46M Sep 24, 2025
FY2025 Jul 31, 2024 $672.93M Sep 24, 2025
FY2025 Jul 31, 2023 $272.40M Sep 24, 2025
FY2024 Jul 31, 2022 $67.54M Sep 19, 2024
FY2023 Jul 31, 2021 ($99.81M) Sep 21, 2023
FY2022 Jul 31, 2020 ($159.89M) Sep 21, 2022
FY2021 Jul 31, 2019 $42.17M Sep 21, 2021
FY2020 Jul 31, 2018 $92.54M Sep 23, 2020
FY2019 Jul 31, 2017 $14.78M Sep 24, 2019
FY2018 Jul 31, 2016 $3.64M Sep 24, 2018

Capital Expenditures (Capex)

Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.

Fiscal Year Period End Value Filed
FY2025 Jul 31, 2025 $71.28M Sep 24, 2025
FY2025 Jul 31, 2024 $75.25M Sep 24, 2025
FY2025 Jul 31, 2023 $65.40M Sep 24, 2025
FY2024 Jul 31, 2022 $49.06M Sep 19, 2024
FY2023 Jul 31, 2021 $58.65M Sep 21, 2023
FY2022 Jul 31, 2020 $89.49M Sep 21, 2022
FY2021 Jul 31, 2019 $118.45M Sep 21, 2021
FY2020 Jul 31, 2018 $62.37M Sep 23, 2020
FY2019 Jul 31, 2017 $50.18M Sep 24, 2019
FY2018 Jul 31, 2016 $42.29M Sep 24, 2018

Total Assets

The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.

Fiscal Year Period End Value Filed
FY2025 Jul 31, 2025 $3.28B Sep 24, 2025
FY2025 Jul 31, 2024 $2.14B Sep 24, 2025
FY2024 Jul 31, 2023 $2.53B Sep 19, 2024
FY2023 Jul 31, 2022 $2.37B Sep 21, 2023
FY2022 Jul 31, 2021 $2.28B Sep 21, 2022
FY2021 Jul 31, 2020 $1.77B Sep 21, 2021
FY2020 Jul 31, 2019 $1.79B Sep 23, 2020
FY2019 Jul 31, 2018 $1.60B Sep 24, 2019
FY2018 Jul 31, 2017 $738.21M Sep 24, 2018
FY2017 Jul 31, 2016 $399.09M Sep 18, 2017

Total Liabilities

All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.

Fiscal Year Period End Value Filed
FY2025 Jul 31, 2025 $3.98B Sep 24, 2025
FY2025 Jul 31, 2024 $2.87B Sep 24, 2025
FY2024 Jul 31, 2023 $3.23B Sep 19, 2024
FY2023 Jul 31, 2022 $3.17B Sep 21, 2023
FY2022 Jul 31, 2021 $3.29B Sep 21, 2022
FY2021 Jul 31, 2020 $2.04B Sep 21, 2021
FY2020 Jul 31, 2019 $1.60B Sep 23, 2020
FY2019 Jul 31, 2018 $1.27B Sep 24, 2019
FY2018 Jul 31, 2017 $521.15M Sep 24, 2018
FY2017 Jul 31, 2016 $465.02M Sep 18, 2017

Stockholders Equity

The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.

Fiscal Year Period End Value Filed
FY2025 Jul 31, 2025 ($694.52M) Sep 24, 2025
FY2025 Jul 31, 2024 ($728.15M) Sep 24, 2025
FY2025 Jul 31, 2023 ($707.42M) Sep 24, 2025
FY2025 Jul 31, 2022 ($800.50M) Sep 24, 2025
FY2024 Jul 31, 2021 ($1.02B) Sep 19, 2024
FY2023 Jul 31, 2020 ($282.58M) Sep 21, 2023
FY2022 Jul 31, 2019 $186.89M Sep 21, 2022
FY2021 Jul 31, 2018 $326.78M Sep 21, 2021
FY2020 Jul 31, 2017 $217.06M Sep 23, 2020
FY2019 Jul 31, 2016 ($285.83M) Sep 24, 2019

Goodwill

An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.

Fiscal Year Period End Value Filed
FY2025 Jul 31, 2025 $185.24M Sep 24, 2025
FY2025 Jul 31, 2024 $185.24M Sep 24, 2025
FY2025 Jul 31, 2023 $184.94M Sep 24, 2025
FY2024 Jul 31, 2022 $185.26M Sep 19, 2024
FY2023 Jul 31, 2021 $185.26M Sep 21, 2023
FY2021 Jul 31, 2020 $185.26M Sep 21, 2021
FY2021 Jul 31, 2019 $185.18M Sep 21, 2021
FY2020 Jul 31, 2018 $87.76M Sep 23, 2020
FY2019 Jul 31, 2017 $16.67M Sep 24, 2019
FY2018 Jul 31, 2016 $0 Sep 24, 2018

Retained Earnings

Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.

Fiscal Year Period End Value Filed
FY2025 Jul 31, 2025 ($4.90B) Sep 24, 2025
FY2025 Jul 31, 2024 ($4.85B) Sep 24, 2025
FY2024 Jul 31, 2023 ($4.63B) Sep 19, 2024
FY2023 Jul 31, 2022 ($4.38B) Sep 21, 2023
FY2023 Aug 1, 2021 ($100.60M) Sep 21, 2023
FY2022 Jul 31, 2021 ($3.63B) Sep 21, 2022
FY2021 Jul 31, 2020 ($2.52B) Sep 21, 2021
FY2020 Jul 31, 2019 ($1.65B) Sep 23, 2020
FY2019 Jul 31, 2018 ($1.03B) Sep 24, 2019
FY2018 Jul 31, 2017 ($730.97M) Sep 24, 2018

Cash & Equivalents

Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.

Fiscal Year Period End Value Filed
FY2025 Jul 31, 2025 $769.50M Sep 24, 2025
FY2025 Jul 31, 2024 $655.27M Sep 24, 2025
FY2025 Jul 31, 2023 $512.93M Sep 24, 2025
FY2024 Jul 31, 2022 $402.85M Sep 19, 2024
FY2023 Jul 31, 2021 $285.72M Sep 21, 2023
FY2022 Jul 31, 2020 $318.74M Sep 21, 2022
FY2021 Jul 31, 2019 $396.68M Sep 21, 2021
FY2020 Jul 31, 2018 $305.98M Sep 23, 2020
FY2019 Jul 31, 2017 $138.36M Sep 24, 2019
FY2018 Jul 31, 2016 $99.21M Sep 24, 2018

EPS (Basic)

Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.

Fiscal Year Period End Value Filed
FY2025 Jul 31, 2025 0 Sep 24, 2025
FY2025 Jul 31, 2024 0 Sep 24, 2025
FY2025 Jul 31, 2023 (1) Sep 24, 2025
FY2024 Jul 31, 2022 (3) Sep 19, 2024
FY2023 Jul 31, 2021 (5) Sep 21, 2023
FY2022 Jul 31, 2020 (4) Sep 21, 2022

EPS (Diluted)

Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.

Fiscal Year Period End Value Filed
FY2025 Jul 31, 2025 0 Sep 24, 2025
FY2025 Jul 31, 2024 0 Sep 24, 2025
FY2025 Jul 31, 2023 (1) Sep 24, 2025
FY2024 Jul 31, 2022 (3) Sep 19, 2024
FY2023 Jul 31, 2021 (5) Sep 21, 2023
FY2022 Jul 31, 2020 (4) Sep 21, 2022

Shares Outstanding

Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.

Fiscal Year Period End Value Filed
FY2022 Jul 31, 2022 226.94M Sep 21, 2022
FY2022 Jul 31, 2021 214.21M Sep 21, 2022
FY2021 Jul 31, 2020 201.95M Sep 21, 2021
FY2020 Jul 31, 2019 188.60M Sep 23, 2020
FY2019 Jul 31, 2018 172.86M Sep 24, 2019
FY2018 Jul 31, 2017 154.64M Sep 24, 2018
FY2017 Jul 31, 2016 46.08M Sep 18, 2017